Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/
View Top Employees from Treadwell Therapeutics, Inc.Website | http://www.treadwelltx.com |
Employees | 50 (50 on RocketReach) |
Founded | 2019 |
Address | 41 Madison Avenue 25th Fl, New York, New York 10010, US |
Technologies |
JavaScript,
HTML,
PHP
+7 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Drug Discovery |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular Treadwell Therapeutics, Inc. employee's phone or email?
Mark Bray is the Founder, Chief Scientific Officer of Treadwell Therapeutics, Inc..
50 people are employed at Treadwell Therapeutics, Inc..
Treadwell Therapeutics, Inc. is based in New York, New York.
The NAICS codes for Treadwell Therapeutics, Inc. are [5417, 54, 541, 541714, 54171].
The SIC codes for Treadwell Therapeutics, Inc. are [873, 87].